- Home
- IBRX vs PAGS Comparison
IBRX vs PAGS Comparison
Compare IBRX & PAGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PAGS
- Stock Information
- Founded
- IBRX 2014
- PAGS 2006
- Country
- IBRX United States
- PAGS Brazil
- Employees
- IBRX N/A
- PAGS N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PAGS EDP Services
- Sector
- IBRX Health Care
- PAGS Technology
- Exchange
- IBRX Nasdaq
- PAGS Nasdaq
- Market Cap
- IBRX 2.4B
- PAGS 2.5B
- IPO Year
- IBRX N/A
- PAGS N/A
- Fundamental
- Price
- IBRX $3.01
- PAGS $7.62
- Analyst Decision
- IBRX Strong Buy
- PAGS Buy
- Analyst Count
- IBRX 5
- PAGS 8
- Target Price
- IBRX $11.35
- PAGS $11.63
- AVG Volume (30 Days)
- IBRX 5.6M
- PAGS 3.8M
- Earning Date
- IBRX 03-03-2025
- PAGS 05-22-2025
- Dividend Yield
- IBRX N/A
- PAGS N/A
- EPS Growth
- IBRX N/A
- PAGS 29.76
- EPS
- IBRX N/A
- PAGS 1.07
- Revenue
- IBRX $14,745,000.00
- PAGS $2,964,269,276.00
- Revenue This Year
- IBRX $621.53
- PAGS $17.66
- Revenue Next Year
- IBRX $163.57
- PAGS $6.18
- P/E Ratio
- IBRX N/A
- PAGS $7.40
- Revenue Growth
- IBRX 2270.58
- PAGS 16.92
- 52 Week Low
- IBRX $2.28
- PAGS $6.11
- 52 Week High
- IBRX $10.53
- PAGS $14.82
- Technical
- Relative Strength Index (RSI)
- IBRX 50.60
- PAGS 45.27
- Support Level
- IBRX $2.69
- PAGS $8.18
- Resistance Level
- IBRX $3.47
- PAGS $8.48
- Average True Range (ATR)
- IBRX 0.21
- PAGS 0.30
- MACD
- IBRX 0.04
- PAGS -0.04
- Stochastic Oscillator
- IBRX 41.77
- PAGS 27.24
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PAGS PagSeguro Digital Ltd.
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused primarily on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.